Mediolanum International Funds Ltd bought a new stake in Evotec SE (NASDAQ:EVO – Free Report) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 140,383 shares of the company’s stock, valued at approximately $512,000.
Several other hedge funds have also recently added to or reduced their stakes in EVO. Vanguard Personalized Indexing Management LLC acquired a new stake in Evotec during the second quarter worth approximately $87,000. Cetera Advisors LLC acquired a new stake in Evotec during the first quarter worth approximately $188,000. DCF Advisers LLC raised its holdings in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Finally, Novo Holdings A S acquired a new stake in Evotec during the second quarter worth approximately $71,183,000. Institutional investors and hedge funds own 5.81% of the company’s stock.
Evotec Stock Down 3.0 %
Shares of Evotec stock opened at $3.52 on Monday. The firm’s fifty day simple moving average is $3.39 and its 200-day simple moving average is $4.41. Evotec SE has a 12 month low of $2.85 and a 12 month high of $12.00. The company has a quick ratio of 1.73, a current ratio of 1.83 and a debt-to-equity ratio of 0.42.
Analyst Ratings Changes
Check Out Our Latest Stock Report on EVO
Evotec Company Profile
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.
Further Reading
- Five stocks we like better than Evotec
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are Dividends? Buy the Best Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Calculate Inflation Rate
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding EVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evotec SE (NASDAQ:EVO – Free Report).
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.